A first study [71] identified two lipidic-related ligands of the Vγ9Vδ2 TCR on tumor targets: apolipoprotein A1 (Apo-A1) and ATP synthase/F1-ATPase (high-affinity apo A-I receptor) Apo-A1, abundant in HDL, are required for optimal activation of Vγ9Vδ2 T cells by tumors expressing F1-ATPase. Here, APOA1 is linked to neoplasm.